New drug duo tested in fight against advanced breast cancer
NCT ID NCT05143229
Summary
This early-stage study is testing the safety of combining two drugs, alpelisib and sacituzumab govitecan, for people with advanced HER2-negative breast cancer that has spread or returned. The main goal is to find the safest and most effective dose of this combination for use in future, larger studies. It involves a small group of 18 participants who have already tried other treatments for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
The University of Kansas Cancer Center - Indian Creek
Overland Park, Kansas, 66211, United States
-
The University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
The University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
The University of Kansas Cancer Center - North Kansas City Hospital
Kansas City, Missouri, 64116, United States
-
The University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
-
The University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
Conditions
Explore the condition pages connected to this study.